Financials
Financial year 2026
PHARMANN from Kuurne, company number BE0845887510, closed financial year 2026 with a result of € 103,664 after tax. For that financial year PHARMANN recorded a gross margin of € 202,199 and equity of € 1.1 million. Compared with financial year 2025, the result moved from € 134,605 to € 103,664. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.
€ 1.1 million
▼ 7% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 103,664
▼ 23% vs 2025
Profit after tax over the fiscal year.
€ 171,565
▲ 71% vs 2025
Cash and bank balances on the last day of the fiscal year.
€ 187,402 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2026
0
Average over the fiscal year, from the social balance sheet.
€ 79,341
▼ 29% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 92,000
▼ 20% vs 2025
€ 23,000 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 5,331
▲ 44% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 20,883
▼ 27% vs 2025
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 184,516 | € 191,811 | € 253,872 | € 202,199 | ▼ 20% |
| Profit after taxes | € 91,251 | € 104,565 | € 134,605 | € 103,664 | ▼ 23% |
| Equity | € 929,731 | € 1,034,297 | € 1,168,902 | € 1,085,164 | ▼ 7% |
| Total debts | € 378,554 | € 320,175 | € 251,147 | € 372,811 | ▲ 48% |
| Cash | € 106,656 | € 97,528 | € 100,611 | € 171,565 | ▲ 71% |
| Land & buildings | € 389,076 | € 389,970 | € 373,286 | € 358,430 | ▼ 4% |
| Retained profit | € 911,181 | € 1,015,747 | € 1,150,352 | € 1,066,614 | ▼ 7% |
| Dividend | € 0 | € 0 | € 0 | € 187,402 | |
| Bank debt | € 161,000 | € 138,000 | € 115,000 | € 92,000 | ▼ 20% |
| Balance sheet total | € 1,308,286 | € 1,354,472 | € 1,420,049 | € 1,457,976 | ▲ 3% |
Key figures of PHARMANN, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to PHARMANN?
What happened at PHARMANN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 103,664 (▼ 23% vs 2025). Source: NBB ↗
- New establishment in Kuurne. KBO
- Start of the company according to the CBE. KBO
In short
From € 91,251 profit in 2023 to € 103,664 profit in 2026.
Paid € 189,565 in corporate taxes since 2023.
Best year ever: 2025, with € 134,605 profit.
Paid out € 187,402 in dividends to the owners in total.
Management
Behind PHARMANN are Dieter Deforce and Ann Vercruysse. It owns 99.2% of Accou Nv itself.
Directors
According to the 2026 annual accounts
Dieter Deforce
Director
Also active at: VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
Establishments
Establishment units
Physical locations of this company
Kortrijksestraat 3
8520 Kuurne
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0845.887.510
- VAT number
- BE 0845.887.510
- Registered office
- Kortrijksestraat 3, 8520 Kuurne
- Names & denominations
- PHARMANN
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 May 2012
- Peppol
- Active · Active since 2 Apr 2025
- Contact
- [email protected] 0478 704 274
- Activities · NACE
Activiteiten van holdings
Holdings